This Aussie Biotech Just Got the Green Light in Germany — And Its Stock Skyrocketed
If you haven’t heard of Argent Biopharma (ASX:RGT), you’re not alone. Most people haven’t — yet. But that might be about to change.
The little-known ASX-listed biotech just scored something huge: approval in Germany for its epilepsy treatment CannEpil®, a high-CBD, low-THC oral formulation aimed at helping patients with drug-resistant epilepsy. This isn’t a clinical fantasy — it’s real. German doctors can now prescribe it under the country’s Special Access Scheme. That means actual market access in one of the biggest healthcare systems in Europe.
And investors are starting to catch on. After the announcement, Argent’s stock jumped, with volume surging as traders began circling the low-cap biotech.
What makes CannEpil different from other cannabinoid-based epilepsy treatments is its patented Self-Nanoemulsifying Drug Delivery System (SNEDDS). The company says this boosts absorption and bioavailability — two big issues in cannabis-based medicines. That patent gives Argent a rare moat in an increasingly crowded niche: cannabinoid pharmaceuticals.
But here’s where it gets really interesting for investors.
A valuation report from Edison Group recently valued CannEpil at USD $327 million — based on market potential, regulatory pathway, and patent protection. Compare that to Argent’s current market cap of around A$12 million, and it’s hard not to take a second look.
Of course, that figure is speculative — but CannEpil is already approved, already in-market, and already being prescribed. That puts Argent in a different league than many ASX-listed small-cap biotechs still stuck in Phase 1 trials. For anyone tracking biotech stocks on the ASX, this one is suddenly on the radar.
The opportunity is also big. In Germany alone, there are around 800,000 people living with epilepsy, and an estimated 30% don’t respond to standard medications. That’s the precise segment CannEpil targets.
Argent isn’t stopping there. The company says it plans to pursue additional approvals across Europe and Australia, and if those markets open up, this could evolve from a one-country story into a broader commercial rollout. Each regulatory win could bring fresh attention — and price movement.
The upside? Big. The risk? Also real. But the setup — low valuation, real approval, strong IP, and a large target market — is exactly the kind of thing early biotech investors look for.
Whether you’re into small-cap ASX stocks, medical cannabis, or just love finding under-the-radar plays before the crowd, Argent Biopharma deserves a closer look.
